| Value | ₹251.7 Cr |
|---|
NSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹944.80
- Market cap
- ₹2,102 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 49.0×Sector 45.9×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Other results update announcements
All →OBSC Perfection Results Update
OBSC Perfection released a press release on unaudited September 2026 half-year results. The release reports record total income, EBITDA and profit.
Mangal Electrical Industries Results Update
Mangal Electrical released a press release on unaudited September 2026 quarter results. CRGO volumes rose about 63% year on year.
Sarda Energy & Minerals Results Update
Sarda Energy & Minerals reported Q2 and H1 FY27 results via press release, with H1 EBITDA at Rs 1,326 Cr (up 3.9%) and PAT at Rs 799 Cr. It also announced a manganese ore block win in Andhra Pradesh through a subsidiary.
Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
Sugs Lloyd Results Update
Sugs Lloyd reported H1 FY27 revenue of Rs.213.31 Crore and PAT of Rs.20.01 Crore, up 73% and 69% YoY. The release also cites Rs.1,068 Crore order book and Rs.395 Crore Q2 order inflow.
Birla Corporation Results Update
Birla Corporation reported September quarter consolidated revenue of ₹2,441 Cr, up 9.3% YoY, but net profit fell 58.9% to ₹37 Cr. The release cites weak cement prices, higher input costs and rainfall disruption.